{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:30:25Z","timestamp":1786739425297,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pain is most common symptom associated with progressive disorder, chronic kidney disease (CKD), and is usually undertreated during the early stages of CKD. So, present review was conducted to evaluate the challenges for the management of pain in CKD patients and addresses the scope for considering Diclofenac as suitable alternative for pain management in CKD patient. The database PubMed and Google Scholar were searched from 1970 to Dec 2020 for literature published in English and all studies, review articles that examined the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in pain management in CKD patients were included. Literatures revealed that there is a considerable challenge in appropriate management of pain in CKD patients include understanding the altered pharmacokinetics and pharmacodynamics of analgesics in CKD patients and the risk of acute interstitial nephritis. The shorter duration of analgesics is acceptable and considered to pose a low risk of acute interstitial nephritis in patients. Considering that Diclofenac has a shorter half-life and high efficacy, it may be well tolerated in patients with CKD. The acceptance of Diclofenac is partly attributed to being a potent COX-2 inhibitor with the lowest IC50 and its rapid onset of action at lowest effective dose. In conclusion, diclofenac may be well tolerated in patients of renal impairment when used at lowest effective dose for shortest dose duration. Diclofenac is worthy of consideration in mild to moderate cases of CKD. For effective pain management, it is vital to evaluate the tolerability and efficacy of the available analgesics critically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_2358_20","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:10:32Z","timestamp":1627557032000},"page":"2450-2456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Safe and appropriate use of diclofenac in chronic kidney disease"],"prefix":"10.4103","volume":"10","author":[{"given":"Sharad","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240828","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1111\/j.1523-1755.2004.00658.x","article-title":"Analgesic prescription patterns among hemodialysis patients in the DOPPS: Potential for underprescription","volume":"65","author":"Bailie","year":"2004","journal-title":"Kidney Int"},{"key":"R2-4-20240828","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/jpm.2007.0142","article-title":"The prevalence and management of chronic pain in end-stage renal disease","volume":"10","author":"Davison","year":"2007","journal-title":"J Palliat Med"},{"key":"R3-4-20240828","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"R5-4-20240828","first-page":"111","article-title":"Pain management in patients with chronic kidney disease","volume":"2","author":"Pham","year":"2009","journal-title":"NDT Plus"},{"key":"R6-4-20240828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2702.2007.01994.x","article-title":"A structured literature review of pain assessment and management of patients with chronic kidney disease","volume":"17","author":"Williams","year":"2008","journal-title":"J Clin Nurs"},{"key":"R7-4-20240828","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ckj\/sfx080","article-title":"2017 update on pain management in patients with chronic kidney disease","volume":"10","author":"Pham","year":"2017","journal-title":"Clin Kidney J"},{"key":"R8-4-20240828","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3399\/bjgp10X502065","article-title":"The role of primary care in managing chronic kidney disease","volume":"60","author":"Brady","year":"2010","journal-title":"Br J Gen Pract"},{"key":"R9-4-20240828","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrneph.2015.85","article-title":"Early chronic kidney disease: Diagnosis, management and models of care","volume":"11","author":"Wouters","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"R10-4-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/fampra\/cms086","article-title":"Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: A systematic review","volume":"30","author":"Nderitu","year":"2013","journal-title":"Fam Pract"},{"key":"R11-4-20240828","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"key":"R12-4-20240828","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2215\/CJN.02330508","article-title":"Chronic kidney disease in the United States: A public policy imperative","volume":"3","author":"Rettig","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-4-20240828","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1038\/s41598-019-46857-7","article-title":"Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: A cross-sectional survey","volume":"9","author":"Duan","year":"2019","journal-title":"Sci Rep"},{"key":"R14-4-20240828","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"R15-4-20240828","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/ndt\/gfq131","article-title":"Prevalence of early stages of chronic kidney disease in apparently healthy central government employees in India","volume":"25","author":"Varma","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R16-4-20240828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2369-10-4","article-title":"Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India using Cockcroft-Gault and Modification of Diet in Renal Disease equation: An observational, cross-sectional study","volume":"10","author":"Singh","year":"2009","journal-title":"BMC Nephrol"},{"key":"R17-4-20240828","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/ndt\/gfh855","article-title":"Prevalence of chronic renal failure in adults in Delhi, India","volume":"20","author":"Agarwal","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R18-4-20240828","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ekir.2018.10.006","article-title":"High prevalence of CKD of unknown etiology in Uddanam, India","volume":"4","author":"Tatapudi","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R19-4-20240828","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1755-6686.2011.00234.x","article-title":"Pain in chronic kidney disease: Prevalence, cause and management","volume":"37","author":"Kafkia","year":"2011","journal-title":"J Ren Care"},{"key":"R20-4-20240828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/pgmj.2008.071191","article-title":"Changing practice to improve pain control for renal patients","volume":"85","author":"Salisbury","year":"2009","journal-title":"Postgrad Med J"},{"key":"R21-4-20240828","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/j.ajkd.2003.08.025","article-title":"Pain in hemodialysis patients: Prevalence, cause, severity, and management","volume":"42","author":"Davison","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R22-4-20240828","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5935\/1806-0013.20140048","article-title":"Analgesics use for kidney failure","volume":"15","author":"Sakata","year":"2014","journal-title":"Revista Dor"},{"key":"R23-4-20240828","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1681\/ASN.2005020157","article-title":"Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients","volume":"16","author":"Weisbord","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R24-4-20240828","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4172\/1758-42721000196","article-title":"Rheumatic and musculoskeletal manifestations in renal hemodialysis patients","volume":"13","author":"Haroon","year":"2018","journal-title":"Int J Clin Rheumatol"},{"key":"R26-4-20240828","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12688\/f1000research.2-28.v2","article-title":"Management of acute and post-operative pain in chronic kidney disease","volume":"2","author":"Parmar","year":"2013","journal-title":"F1000Res"},{"key":"R27-4-20240828","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/annrheumdis-2012-202709","article-title":"Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: A prospective cohort study","volume":"73","author":"Moller","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R28-4-20240828","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MNH.0000000000000473","article-title":"The case for cautious consumption: NSAIDs in chronic kidney disease","volume":"28","author":"Sriperumbuduri","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R29-4-20240828","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/gfn745","article-title":"Acetaminophen, aspirin and progression of advanced chronic kidney disease","volume":"24","author":"Evans","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R30-4-20240828","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM198905113201903","article-title":"Analgesic use and chronic renal disease","volume":"320","author":"Sandler","year":"1989","journal-title":"N Engl J Med"},{"key":"R31-4-20240828","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJM199412223312502","article-title":"Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs","volume":"331","author":"Perneger","year":"1994","journal-title":"N Engl J Med"},{"key":"R32-4-20240828","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000168002","article-title":"Regular analgesic intake and the risk of end-stage renal failure","volume":"9","author":"Pommer","year":"1989","journal-title":"Am J Nephrol"},{"key":"R33-4-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF03160941","article-title":"Acetaminophen-induced nephrotoxicity: Pathophysiology, clinical manifestations, and management","volume":"4","author":"Mazer","year":"2008","journal-title":"J Med Toxicol"},{"key":"R34-4-20240828","first-page":"e5003","article-title":"A rare case of acetaminophen toxicity leading to severe kidney injury","volume":"11","author":"Saleem","year":"2019","journal-title":"Cureus"},{"key":"R35-4-20240828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/ijms18010223","article-title":"What do we know about opioids and the kidney","volume":"18","author":"Mallappallil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R36-4-20240828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-6386(03)00645-0","article-title":"Analgesia in patients with ESRD: A review of available evidence","volume":"42","author":"Kurella","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R37-4-20240828","first-page":"5","article-title":"The use of opioid analgesia in end-stage renal disease patients managed without dialysis: Recommendations for practice","volume":"21","author":"Murtagh","year":"2007","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"R38-4-20240828","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1213\/01.ane.0000287675.15225.0b","article-title":"Mechanisms of morphine enhancement of spontaneous seizure activity","volume":"105","author":"Saboory","year":"2007","journal-title":"Anesth Analg"},{"key":"R39-4-20240828","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2215\/CJN.05180418","article-title":"Clinical pharmacology considerations in pain management in patients with advanced kidney failure","volume":"14","author":"Davison","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R40-4-20240828","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: Are they safe","volume":"76","author":"Baker","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R41-4-20240828","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199733030-00003","article-title":"Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls","volume":"33","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R42-4-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009747809097212","article-title":"Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren","volume":"7","author":"Riess","year":"1978","journal-title":"Scand J Rheumatol Suppl"},{"key":"R43-4-20240828","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00568201","article-title":"The pharmacokinetics of diclofenac sodium following intravenous and oral administration","volume":"16","author":"Willis","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"R44-4-20240828","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2165\/00003495-198835030-00004","article-title":"Diclofenac sodium: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy","volume":"35","author":"Todd","year":"1988","journal-title":"Drugs"},{"key":"R45-4-20240828","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1073\/pnas.1517642113","article-title":"Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-\u03baB and NFAT transcriptional pathways","volume":"113","author":"Kirkby","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-4-20240828","doi-asserted-by":"crossref","first-page":"45763","DOI":"10.1074\/jbc.M305481200","article-title":"A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385","volume":"278","author":"Rowlinson","year":"2003","journal-title":"J Biol Chem"},{"key":"R47-4-20240828","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers","volume":"40","author":"Van Hecken","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R48-4-20240828","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpba.2010.08.001","article-title":"Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry","volume":"54","author":"Cao","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"R49-4-20240828","first-page":"1705","article-title":"Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases","volume":"271","author":"Patrignani","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R50-4-20240828","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"key":"R51-4-20240828","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0165-6147(99)01385-1","article-title":"Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future","volume":"20","author":"Marnett","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"R52-4-20240828","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3390607","article-title":"Kinetic basis for selective inhibition of cyclo-oxygenases","volume":"339","author":"Gierse","year":"1999","journal-title":"Biochem J"},{"key":"R53-4-20240828","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s000110050752","article-title":"In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs)","volume":"50","author":"Dannhardt","year":"2001","journal-title":"Inflamm Res"},{"key":"R54-4-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2125.2003.01712.x","article-title":"Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: No relationship to the CYP2C9 genetic polymorphism in humans","volume":"55","author":"Kirchheiner","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R55-4-20240828","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/art.20424","article-title":"The discovery and development of antiinflammatory drugs","volume":"50","author":"Brune","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R56-4-20240828","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrrheum.2010.141","article-title":"Using pharmacokinetic principles to optimize pain therapy","volume":"6","author":"Brune","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R57-4-20240828","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01037953","article-title":"Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis","volume":"25","author":"Fowler","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"R58-4-20240828","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00613526","article-title":"Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation","volume":"31","author":"Fowler","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R59-4-20240828","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-015-0392-z","article-title":"Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology","volume":"75","author":"Altman","year":"2015","journal-title":"Drugs"},{"key":"R60-4-20240828","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF02031615","article-title":"Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis","volume":"4","author":"Sepp\u00e4l\u00e4","year":"1985","journal-title":"Clin Rheumatol"},{"key":"R61-4-20240828","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/BF01837915","article-title":"Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: Effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen","volume":"44","author":"Sacerdote","year":"1995","journal-title":"Inflamm Res"},{"key":"R62-4-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0002-9343(86)90085-9","article-title":"Worldwide safety experience with diclofenac","volume":"80","author":"Catalano","year":"1986","journal-title":"Am J Med"},{"key":"R63-4-20240828","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.joms.2016.04.003","article-title":"Comparative assessment of the effect of ibuprofen and etodolac on edema, trismus, and pain in lower third molar surgery: A randomized clinical trial","volume":"74","author":"Silva de Oliveira","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"R64-4-20240828","first-page":"237","article-title":"Analgesic efficacy of low-dose diclofenac versus paracetamol and placebo in postoperative dental pain","volume":"17","author":"Kubitzek","year":"2003","journal-title":"J Orofac Pain"},{"key":"R65-4-20240828","doi-asserted-by":"crossref","first-page":"284","DOI":"10.15537\/smj.2017.3.16023","article-title":"Comparison of paracetamol, ibuprofen, and diclofenac potassium for pain relief following dental extractions and deep cavity preparations","volume":"38","author":"Gazal","year":"2017","journal-title":"Saudi Med J"},{"key":"R67-4-20240828","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1185\/03007995.2010.486301","article-title":"Diclofenac: An update on its mechanism of action and safety profile","volume":"26","author":"Gan","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R68-4-20240828","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1213\/ANE.0b013e3182691bf9","article-title":"A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: A multicenter, double-blind, randomized, multiple-dose study","volume":"115","author":"Gan","year":"2012","journal-title":"Anesth Analg"},{"key":"R69-4-20240828","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clinthera.2014.10.018","article-title":"Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac","volume":"37","author":"Desjardins","year":"2015","journal-title":"Clin Ther"},{"key":"R70-4-20240828","first-page":"21","article-title":"Diclofenac\/misoprostol: The European clinical experience","volume":"51","author":"McKenna","year":"1998","journal-title":"J Rheumatol Suppl"},{"key":"R71-4-20240828","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40264-019-00900-8","article-title":"Coronary risks associated with diclofenac and other NSAIDs: An update","volume":"43","author":"Moore","year":"2020","journal-title":"Drug Saf"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2358_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:53Z","timestamp":1786735733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_2358_20"}},"subtitle":["An Indian perspective"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2358_20","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}